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Primary vesicoureteric reflux (VUR) affects 1%–2% of whites, and reflux nephropathy (RN) causes up to 15% of
end-stage renal failure in children and adults. There is a 30–50-fold increased incidence of VUR in first-degree
relatives of probands, compared with the general population. We report the results of the first genomewide search
of VUR and RN; we studied seven European families whose members exhibit apparently dominant inheritance.
We initially typed 387 polymorphic markers spaced, on average, at 10 cM throughout the genome; we used the
GENEHUNTER program to provide parametric and nonparametric linkage analyses of affected individuals. The
most positive locus spanned 20 cM on 1p13 between GATA176C01 and D1S1653 and had a nonparametric LOD
score (NPL) of 5.76 ( ) and a parametric LOD score of 3.16. Saturation with markers at 1-cM intervalsP = .0002
increased the NPL to 5.94 ( ). Hence, VUR maps to a locus on chromosome 1. There was evidence ofP = .00009
genetic heterogeneity at the chromosome 1 locus, and 12 additional loci were identified genomewide, with P !
. No significant linkage was found to 6p, where a renal and ureteric malformation locus has been reported, or.05
to PAX2, mutations of which cause VUR in renal-coloboma syndrome. Our results support the hypothesis that
VUR is a genetic disorder.
Vesicoureteric reflux (VUR [MIM 193000]) is the ret-
rograde passage of urine from the bladder into the upper
urinary tract. VUR may occur as a secondary effect of
anatomical or neurological bladder outflow obstruction.
However, the primary form of the disorder occurs in the
absence of these features, with an incidence in infants
of 1%–2% (Peters et al. 1967; Bailey 1975). Almost
30% of children presenting with urinary tract infection
(UTI) have VUR, and the reflux of infected urine into
the kidney in the presence of compound papillae can
cause acute pyelonephritis and subsequent renal paren-
chymal scarring (Smellie and Prescod 1986). In addition,
some infants born with VUR have associated dysplastic
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or hypoplastic renal malformations, which themselves
impair renal function (Hinchliffe et al. 1992; Risdon et
al. 1993). Reflux nephropathy (RN), the renal disease
associated with VUR, accounts for up to 15% of end-
stage renal failure in children and adults (Kincaid-Smith
et al. 1984).
Previous studies demonstrated that VUR and RN can
occur in families, and systematic studies of first-degree
relatives of individuals affected with VUR show a
30%–50% incidence of VUR, which implies that genetic
factors play an important role in the pathogenesis (Noe
1992; Noe et al. 1992). Different modes of inheritance
of VUR have been suggested, including a dominant
single gene (Chapman et al. 1985) and polygenic inher-
itance (DeVargas et al. 1978). Previous studies have sug-
gested a urinary tract malformation locus on chromo-
some 6p on the basis of two lines of evidence: a balanced
translocation including 6p and association with HLA
types (Macintosh et al. 1989; Izquierdo et al. 1992; Gro-
enen et al. 1998). VUR can also occur as part of complex
syndromes (Winter and Baraitser 1998) such as the re-
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nal-coloboma syndrome, which is caused by PAX2 mu-
tations on chromosome 10q (Sanyanusin et al. 1995).
Recent work has found an association between diverse
renal tract malformations and a polymorphism of the
angiotensin II receptor type 2 (AT2) on Xq (Nishimaura
et al. 1999). Furthermore, studies in mice demonstrate
that the function and interaction of numerousmolecules,
including transcription factors, growth factors, and cell-
adhesion molecules, are critical for the normal devel-
opment of the urinary tract (Woolf and Winyard 1998).
This raises the possibility that primary, nonsyndromic
VUR may be genetically heterogeneous.
We performed a genomewide search for susceptibility
loci for primary VUR of seven European kindreds with
three to seven affected individuals in each family and an
apparently dominant pattern of inheritance. The seven
families that we studied were assessed by pediatric and
adult nephrologists. VUR was diagnosed by cystogram
and RN by intravenous pyelogram or isotope renogram.
There was no evidence of secondary causes of VUR or
other clinical features that suggested a syndromic di-
agnosis. In each family, at least one individual presented
with symptomatic renal disease and had been established
by radiological investigations to have VUR, RN, or both,
as indicated in figure 1. This prompted further inquiry
into the rest of the family. Some family members had
already been investigated and diagnosed as having VUR,
RN, or both, but some affected relatives were subse-
quently diagnosed by radiological screening. We chose
to analyze only affected individuals, because VUR can
regress with age (Tamminen-Mobius et al. 1992), and,
furthermore, not all individuals had a cystogram, an
investigation that was not thought to be clinically rel-
evant in asymptomatic adults. All individuals in whom
VUR, RN, or both were not clinically proven were clas-
sified as having unknown status. Specifically, the pres-
ence of “soft” renal symptoms and signs such as UTI or
hypertension were not regarded as precise enough for a
positive diagnosis of VUR or RN, so these individuals
were labeled as having unknown status. Informed con-
sent was obtained from individuals before they were
included in the study.
DNA was extracted from peripheral blood leukocytes
by standard techniques. The primers for the markers
were obtained from Research Genetics. Set 6.0 was used
for chromosomes 2–7, 11, 12, 15, 17–20, and X in ped-
igrees 1–5. The remainder of the chromosomes in ped-
igrees 1–5 and all chromosomes in pedigrees 6 and 7
were analyzed with fluorescently labeled primers of set
8.0 (Research Genetics). A total of 387markerswas used
in the analysis, and 10 additional markers were used to
saturate the region on chromosome 1. Semiautomated
fluorescent genotyping was undertaken with the ABI 377
Genescan/Genotyper system by comparison of the frag-
ment sizes with an internal standard. The PCR products
of the remainder of the primers were labeled with ra-
dioactive a[32P]-CTP and the products separated with a
nondenaturing polyacrylamide gel system. The average
heterozygosity of the markers was 0.76, and the average
spacing was 10 cM.
The program GENEHUNTER (Kruglyak et al. 1996)
was used to compute multipoint parametric and non-
parametric linkage analysis by use of data from the seven
pedigrees. An analysis of only affected family members
was performed by use of clinical criteria as described.
The genetic model for VUR used in the parametric anal-
ysis was the most likely model predicted by the segre-
gation analysis of Chapman et al. (1985): gene frequency
of 1% and a dominant disorder and phenocopy of 1%.
Heterogeneity (a) at each locus was also estimated by
GENEHUNTER. Stringent criteria for statistical signif-
icance of genomewide scans in sibling pairs were used:
was suggestive of linkage, and wasP ! .0007 P ! .00002
significant linkage (Lander and Kruglyak 1995), al-
though it was recognized that the families we studied
might correspond to a dominant disorder with P !
, suggestive of linkage, and , signifi-.0017 P ! .000049
cant linkage. All areas with are reported (LanderP ! .05
and Kruglyak 1995). Figure 1 shows the pedigrees of
the seven families included in the study. Table 1 shows
the most significant regions (with on a nonpar-P ! .05
ametric analysis) genomewide by generation of a mul-
tipoint analysis on the entire data set by GENE-
HUNTER. Results are presented for affected individuals
with VUR, RN, or both.
The most positive susceptibility locus was a 20-cM
interval on chromosome 1 between GATA176C01 and
D1S1653 in cytogenetic band 1p13. The nonparametric
LOD (NPL) score was 5.48 ( ) on the initialP = .0002
genomewide set of markers. Saturation of the region
with markers spaced at 1-cM intervals increased theNPL
score to 5.94 ( ). The parametric LOD scoreP = .00009
for this region, under a dominant genetic model with a
gene frequency of 0.01 and a phenocopy of 0.01, was
3.12 ( ) and was 3.17 ( ) with saturation ofa = .78 a = .78
the region.
Pedigree 6 had the highest parametric LOD score at
this locus (2.16), and both pedigrees 1 and 2 had neg-
ative parametric LOD scores. Heterogeneity at this locus
was 0.78. It was not possible to establish whether the
additional pedigrees mapped to this region, since the
maximum parametric LOD score was 0.85 in pedigree
4. Because pedigree 6 weights the chromosome 1 data,
the genomewide analysis was repeated without this ped-
igree, to search for additional loci. The results for this
analysis are presented in table 2 and show that the next
most positive locus was on chromosome 20 between
D20S477 and D20S481, with a parametric LOD score
of 2.90 and an NPL of 3.42 ( ). Pedigree 6 hadP = .003
a negative LOD score (1.74) at this locus.
Figure 1 Pedigrees used in the genomewide analysis. Affected individuals have either VUR, as established by cystogram, or RN, as
established by intravenous pyelogram or isotope renogram. Individuals who have a history of urinary tract problems such as UTI or hypertension
but have not had the appropriate radiological investigations to clarify whether they have VUR or RN were labeled as having unknown status
in the statistical analysis.
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Table 1
Summary of GENEHUNTER Analysis
Chromosome
(Distance
[cM]) Markers
Parametric
LOD Score
(a)
NPL
Score P LODs (Pedigrees) at Maximum P
1 (149–166) GATA176CO1–D1S1653 3.12 (.78) 5.48 .0002 .46 (1), 1.08 (2), .56 (3), .85 (4), .27 (5), 2.16 (6), .56 (7)
2 (55–68) D2S1788–D2S1352 1.17 (.31) 3.35 .005 .13 (1), .86 (2), .65 (3), .54 (4), .01 (5), 1.02 (6), .11 (7)
3 (37–66) GATA164B08–D3S1768 2.43 (.87) 2.95 .009 .45 (1), 1.25 (2), .16 (3), .09 (4), .19 (5), 1.06 (6), .19 (7)
3 (117–184) GATA128C02–D3S1763 1.61 (.98) 3.00 .008 1.21 (1), .13 (2), .15 (3), .11 (4), .27 (5), .24 (6), .51 (7)
8 (25–29) D8S1106–D8S1145 1.05 (.45) 2.38 .02 .46 (1), 1.32 (2), .20 (3), .84 (4), .27 (5), .85 (6), .91 (7)
9 (64–69) D9S1122–D9S922 .60 (.34) 2.16 .03 1.19 (1), 1.08 (2), .52 (3), .95 (4), .27 (5), .74 (6), .36 (7)
9 (143–145) ATA59H06–D9S158 .93 (.48) 1.87 .04 1.14 (1), .85 (2), .44 (3), 1.70 (4), .07 (5), .68 (6), .50 (7)
13 (90–117) D13S793–D13S285 2.03 (.99) 2.34 .02 .03 (1), .81 (2), .31 (3), .72 (4), .04 (5), .09 (6), .55 (7)
20 (3–35) D20S103–D20S470 2.79 (.99) 2.75 .01 .37 (1), .95 (2), .50 (3), .84 (4), .27 (5), .53 (6), .38 (7)
20 (45–53) D20S477–D20S481 1.77 (.74) 2.92 .009 1.20 (1), .85 (2), .55 (3), .61 (4), .27 (5), 1.74 (6), .54 (7)
22 (24–25) GCT10C10–D22S689 .91 (.48) 2.19 .02 1.11 (1), .74 (2), .55 (3), 1.17 (4), .24 (5), .23 (6), .28 (7)
22 (40–44) D22S685–D22S445 1.20 (.71) 2.04 .03 .28 (1), .39 (2), .56 (3), 1.4 (4), .26 (5), .78 (6), .30 (7)
X (70–84) GATA144D04–DXS6800 .58 (.75) 1.9 .04 .01 (1), .43 (2), .50 (3), .40 (4), .05 (5), .36 (6), .39 (7)
NOTE.—Areas with are described. The most positive region is on chromosome 1, with genetic heterogeneity at this locus, sinceP ! .05
pedigrees 1 and 2 have negative LOD scores.
Table 2
Summary of GENEHUNTER Analysis Excluding Pedigree 6
Chromosome
(Distance
[cM]) Markers
Parametric
LOD Score
NPL
Score P
1 (152–166) GATA176CO1–D1S1653 .7 2.65 .01
3 (61–65) GATA164B08–D3S1768 1.01 1.90 .04
3 (114–177) GATA128C02–D3S1763 1.89 3.79 .004
8 (24–30) D8S1106–D8S1145 .86 2.57 .01
13 (96–113) D13S793–D13S285 2.08 2.37 .02
20 (2–36) D20S103–D20S470 1.22 1.57 .02
20 (42–54) D20S477–D20S481 2.90 3.42 .003
22 (24–28) GCT10C10–D22S689 .3 1.9 .04
X (74–84) GATA175DO3–DXS7132 .89 2.04 .03
NOTE.—The most positive area is now on chromosone 20, with a
parametric LOD score that approaches 3.0. Areas with areP ! .05
described.
Prior to the genome scan, a number of regions were
considered to be candidates for linkage to VUR and RN,
including chromosome 6p (the HLA locus), chromosome
10q (where the genes PAX2, RET, and FGFR2 are lo-
cated), and the X chromosome (where AT2 is located).
There were no areas on chromosome 6p and chromo-
some 10q with . However, there was a locus onP ! .05
the X chromosome that was worthy of report ( ).P = .04
In this study, we present the results of the first ge-
nomewide search in primary, nonsyndromic VUR and
its nephropathy. We have investigated seven large ped-
igrees in which inheritance of VUR appears to be dom-
inant. Our analysis identifies a 20-cM locus on chro-
mosome 1 that is highly suggestive of linkage (P =
). The criteria of Lander and Kruglyak (1995).00009
assume no prior genetic model, and, when we use what
is considered to be the most likely model for VUR on
the basis of segregation analysis (Chapman et al. 1985),
a significant parametric LOD score of 3.17 is reached.
The order and level of significance of the nonparametric
and parametric scores correspond closely, which suggests
that the dominant model previously suggested for VUR
(Chapman et al. 1985) is likely to be correct.
A number of biological processes, including those in-
volved in development, neoplasia, and inflammation,
could be involved in the pathogenesis of VUR and its
nephropathy, and genes implicated in these processes are
potential candidates for VUR. The region on chromo-
some 1 contains several interesting candidate genes. The
ras-related protein 1A (RAP1A or KREV1) contains
GTP-binding motifs and shares 50% amino acid ho-
mology with RAS proteins. The expression of KREV1
has been noted to be reduced in some tumors (Pizon et
al. 1988; Kitayama et al. 1989). Another potential can-
didate is the Ras homolog gene family member C gene.
This gene is a member of the Ras superfamily of small
GTP-binding proteins, which are a large group of pro-
teins that are involved in signal transduction, prolifer-
ation, vesicle trafficking, and regulation of the actin cy-
toskeleton, which could be involved in developmental
abnormalities such as VUR (Madaule and Axel 1985;
Maekawa et al. 1999). Additional interesting genes for
further study in the interval on chromosome 1 include
glutathione s-transferase, the absence of which is asso-
ciated with an increased risk of bladder cancer (Golka
et al. 1997), and colony-stimulating factor 1, which is
implicated in renal inflammation (Wada et al. 1997).
However, since pedigrees 1 and 2 have negative par-
ametric LOD scores at the locus on chromosome 1, there
is evidence for genetic heterogeneity, suggesting that the
most likely mode of inheritance for VUR is dominant,
with different genes acting in different families. More
pedigrees need to be tested to confirm or refute the
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regions found in this study and to narrow candidate
regions. It may then become apparent that the inheri-
tance of VUR is dominant in only a proportion of fam-
ilies and that the overall inheritance of VUR in the pop-
ulation is polygenic. We have collected 40 additional
pedigrees with VUR for investigation, and, of the sam-
ples collected, few had such dominant-looking pedigrees
as those used in this study. At present, it remains unclear
whether the diagnosis of VUR has been missed in older
and uninvestigated individuals and inheritance in these
pedigrees is dominant or whether these individuals are
really unaffected, which suggests polygenic inheritance.
Furthermore, a positive diagnosis of VUR and its ne-
phropathy requires invasive radiological investigation,
with cystogram, isotope renogram, or intravenous pye-
logram, the nature of which may limit the definitive test-
ing of asymptomatic individuals, particularly children,
and acts to reduce the power of pedigrees included in a
genetic study of VUR.
The testing of additional data sets may also uncover
further loci for examination. We did not find positive
results in areas that have previously been reported as
renal malformation loci, including the short arm of chro-
mosome 6 (Macintosh et al. 1989; Izquierdo et al. 1992;
Groenen et al. 1998) and the long arm of chromosome
10, where the gene PAX2 (Sanyanusin et al. 1995) is
located. The exclusion of the PAX2 locus is not sur-
prising, because this has been reported by other authors
who performed SSCP analysis and sequencing of PAX2
in individuals with nonsyndromic cases of VUR (Choi
et al. 1998). Furthermore, there was no evidence of vi-
sual defects in the pedigrees analyzed in this study. How-
ever, on the X chromosome, there is a region with P =
that includes the locus of the postulated renal tract.04
malformation gene AT2 (Nishimaura et al. 1999). This
locus is worthy of further examination, but the popu-
lation reported to have an association between an in-
tronic polymorphism of AT2 and renal tract malfor-
mations was apparently male infants with sporadic
diverse renal tract malformations; conversely, our ped-
igrees probably represent a different group of older in-
dividuals with recurrent UTI and a strong family history
of VUR. There are more affected females than affected
males in our pedigrees, a fact that has been reported by
other authors (MacGregor and Freeman 1975), which
might suggest a modifying gene on the X chromosome,
although it has been noted that, in individuals who pre-
sent with UTI, VUR is found with a similar frequency
in the two sexes (Kelais 1971).
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